Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer

Starting soon · Phase 2

Conditions studied: Colorectal Cancer Metastatic, Peritoneal (Metastatic) Cancer, Peritoneal Metastasis, Colorectal Cancer (CRC), MSS Metastatic Colorectal Cancer

In brief

The goal of this phase II randomized controlled clinical trial is to evaluate whether adding lubiprostone to standard postoperative maintenance therapy can delay disease progression and recurrence in adult patients with colorectal cancer and peritoneal metastases (PM-CRC) who have undergone cytoreductive surgery with or without HIPEC after systemic treatment. The main questions it aims to answer are: Does lubiprostone plus maintenance therapy improve the 1-year progression-free survival (PFS) rate compared with maintenance therapy alone? Is lubiprostone safe and feasible for long-term use during the maintenance period in this PM-CRC population? Researchers will compare lubiprostone + maintenance therapy versus maintenance therapy alone to see if the addition of lubiprostone prolongs PFS, reduces the risk of distant metastasis, improves overall survival, and maintains or improves quality of life. Participants will: Be randomly assigned to receive maintenance therapy with lubiprostone or maintenance therapy alone after surgery (CRS ± HIPEC) and prior systemic therapy, according to the study protocol. Undergo scheduled follow-up assessments for disease status (progression/recurrence), survival outcomes, treatment-related toxicity, and quality of life using the EORTC QLQ-C30 (v3.0) questionnaire.

Key facts

Study ID

NCT07405736

Run by

Sun Yat-sen University

People needed

124

Starts

2026-02-24

Expected to finish

2028-06-01

Last updated by the study team

2026-02-12

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Voluntarily participates and provides written informed consent.
• Histologically confirmed colon/rectal adenocarcinoma with molecular status confirmed as pMMR or MSS.
• Cytoreductive surgery (CRS) achieves CC0/CC1 cytoreduction.
• No extraperitoneal metastasis prior to treatment.
• ECOG performance status 0-1 with adequate organ function per protocol requirements.

You may not qualify if…

• Extensive multisystem metastases on baseline imaging assessment.
• Tumor carrying BRAF V600E mutation.
• dMMR/MSI-H, or confirmed pathogenic POLE/POLD1 mutation(s).
• Cachexia or decompensated organ dysfunction.
• History of another malignancy within the past 5 years.
• Known or suspected hypersensitivity/allergy to the study drug or related formulations.
• Multiple primary cancers.
• Any serious disease or other medical, psychological, or social condition that, in the investigator's judgment, may compromise participant safety or affect study results.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.